Zofran Removed From the Market Over Potential Cardiac Threat
A potential threat posed to a patient’s health has led to the complete market removal of Zofran, an anti-nausea drug typically given to individuals dealing with the side effects of chemotherapy. The Food and Drug Administration expects that all single IV 32 milligram doses of the drug will be taken off the market by the early part of 2013. The agency previously expressed their concern over a dangerous heart rhythm condition called Torsades de Pointes in a letter made available at the end of June. Until such time that the product can be removed from circulation, the FDA tells doctors that Ondansetron oral dosing should remain effective, and they advise medical professionals to report any side effects, including cardiac issues, that occur in conjunction with Zofran.
For more about the market removal, follow this link.